On September 19, 2023, Mark A. Velleca, M.D., Ph.D., notified G1 Therapeutics, Inc. (the ?Company?) of his decision to resign from the Board of Directors (the ?Board?) of the Company effective as of September 30, 2023. Dr. Velleca was a member of the Board since May 2014. Dr. Velleca will continue to serve as a senior advisor to the Company pursuant to the terms of a Senior Advisor Agreement dated September 29, 2020 (the ?Agreement?), as amended by that certain First Amendment to Senior Advisor Agreement, dated as of September 20, 2023 (the ?Amendment?).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.77 USD | -4.22% | +6.24% | +56.39% |
May. 01 | Transcript : G1 Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 | |
May. 01 | Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.39% | 249M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- GTHX Stock
- News G1 Therapeutics, Inc.
- G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023